MiniMed Q1 FY27 net sales $843M +16.6%; raises FY27 organic growth to ~10.5%

MiniMed Group, Inc.

Net sales $843M, +16.6% as reported, +15.8% organic; U.S. +13.1% to $240M, international +18.1% to $603M.
Worldwide NPS ~34,000 (+7.7% YoY); CGM attachment rate 69% (+~100bps QoQ).
Raises FY27 organic revenue growth to ~10.5% (from ~10%); reaffirms adjusted EBITDA margin ~16%.
Pipeline: MiniMed Fit FDA submission ahead of Fall; Flex CE Mark; Vivera pivotal enrollment complete; next-gen sensor IDE approved.
U.S. launch of MiniMed Flex with Instinct started Aug 17; Medicare coverage expanded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.